Clement Richard Boland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6281397/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research, 1998, 58, 5248-57.	0.9	2,999
2	Microsatellite Instability in Colorectal Cancer. Gastroenterology, 2010, 138, 2073-2087.e3.	1.3	1,779
3	Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2017, 153, 307-323.	1.3	512
4	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastroenterology, 2014, 147, 502-526.	1.3	397
5	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1159-1179.	0.4	363
6	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2014, 147, 903-924.	1.3	322
7	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2017, 152, 1217-1237.e3.	1.3	268
8	Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis, 2014, 35, 2731-2739.	2.8	242
9	Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut, 2014, 63, 635-646.	12.1	238
10	Epigenetics of Colorectal Cancer. Gastroenterology, 2012, 143, 1442-1460.e1.	1.3	209
11	Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression. Nature Medicine, 1995, 1, 902-909.	30.7	201
12	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis, 2015, 36, 355-367.	2.8	200
13	Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut, 2017, 66, 654-665.	12.1	185
14	The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. The Lancet Gastroenterology and Hepatology, 2022, 7, 262-274.	8.1	177
15	A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer. PLoS ONE, 2012, 7, e45357.	2.5	164
16	Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population. Cancer Prevention Research, 2011, 4, 9-22.	1.5	153
17	Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2016, 150, 758-768.e11.	1.3	151
18	Identification of a Metastasis-Specific MicroRNA Signature in Human Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	139

CLEMENT RICHARD BOLAND

#	Article	IF	CITATIONS
19	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A stateâ€ofâ€theâ€science review. Cancer, 2016, 122, 2633-2645.	4.1	131
20	Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clinical Cancer Research, 2015, 21, 4234-4242.	7.0	128
21	Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget, 2015, 6, 2981-2991.	1.8	128
22	Report From the Jerusalem Workshop on Lynch Syndrome-Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 2010, 138, 2197.e1-2197.e7.	1.3	124
23	A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clinical Cancer Research, 2003, 9, 383-90.	7.0	120
24	Familial Colonic Cancer Without Antecedent Polyposis. Annals of Internal Medicine, 1984, 100, 700.	3.9	119
25	Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1528-1545.	0.4	119
26	Evolution of the Nomenclature for the Hereditary Colorectal Cancer Syndromes. Familial Cancer, 2005, 4, 211-218.	1.9	118
27	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. Ca-A Cancer Journal for Clinicians, 2018, 68, 217-231.	329.8	117
28	Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut, 2017, 66, 107-117.	12.1	110
29	Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2014, 80, 543-562.	1.0	106
30	Novel Evidence for Curcumin and Boswellic Acid–Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. Cancer Prevention Research, 2015, 8, 431-443.	1.5	102
31	Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps. Cancer Prevention Research, 2012, 5, 574-582.	1.5	100
32	Aberrant DNA Methylation in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair Deficiency. Gastroenterology, 2010, 138, 1854-1862.e1.	1.3	95
33	Guidelines on Genetic Evaluation and Management of Lynch Syndrome. Diseases of the Colon and Rectum, 2014, 57, 1025-1048.	1.3	90
34	Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes. Journal of the National Cancer Institute, 2016, 108, .	6.3	84
35	MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer. Clinical Cancer Research, 2010, 16, 5402-5413.	7.0	80
36	A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer. Scientific Reports, 2018, 8, 575.	3.3	80

#	Article	IF	CITATIONS
37	How many mutations does it take to make a tumor?. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14675-14677.	7.1	78
38	<i>De novo</i> constitutional <i>MLH1</i> epimutations confer earlyâ€onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. International Journal of Cancer, 2011, 128, 869-878.	5.1	77
39	The History of Lynch Syndrome. Familial Cancer, 2013, 12, 145-157.	1.9	76
40	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications. Modern Pathology, 2017, 30, 599-609.	5.5	74
41	MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 274-282.	7.4	68
42	Low Frequency of Lynch Syndrome Among Young Patients With Non-Familial Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2010, 8, 966-971.e1.	4.4	66
43	The Carbohydrate Composition of Mucin in Colonic Cancer. Gastroenterology, 1990, 98, 1170-1177.	1.3	60
44	Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2016, 111, 337-346.	0.4	59
45	Genetics and Genetic Testing in Hereditary Colorectal Cancer. Gastroenterology, 2015, 149, 1191-1203.e2.	1.3	57
46	Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112, 37-53.	0.4	56
47	Recommendations on fecal immunochemical testing to screen forÂcolorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointestinal Endoscopy, 2017, 85, 2-21.e3.	1.0	55
48	A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated ColorectalÂCancer. Gastroenterology, 2017, 153, 1634-1646.e8.	1.3	54
49	Molecular Genetics of Hereditary Nonpolyposis Colorectal Cancer. Annals of the New York Academy of Sciences, 2000, 910, 50-61.	3.8	52
50	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nature Communications, 2014, 5, 5191.	12.8	51
51	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
52	IGFBP3 Methylation Is a Novel Diagnostic and Predictive Biomarker in Colorectal Cancer. PLoS ONE, 2014, 9, e104285.	2.5	49
53	Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. Journal of the National Cancer Institute, 2016, 108, .	6.3	49
54	Non-coding RNA: It's Not Junk. Digestive Diseases and Sciences, 2017, 62, 1107-1109.	2.3	49

#	Article	IF	CITATIONS
55	Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on ColorectalÂCancer. Gastroenterology, 2017, 152, 1605-1614.	1.3	46
56	Technical Factors Involved in the Measurement of Circulating MicroRNA Biomarkers for the Detection of Colorectal Neoplasia. PLoS ONE, 2014, 9, e112481.	2.5	44
57	Somatic evolution of cancer cells. Seminars in Cancer Biology, 2005, 15, 436-450.	9.6	40
58	Microsatellite Alterations With Allelic Loss at 9p24.2 SignifyÂLess-Aggressive Colorectal Cancer Metastasis. Gastroenterology, 2016, 150, 944-955.	1.3	34
59	Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1312-1322.	7.0	34
60	Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prevention Research, 2017, 10, 208-218.	1.5	31
61	Historical Perspective on Familial Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 192-200.	4.5	31
62	Early-Age Onset Colorectal Neoplasia in Average-Risk Individuals Undergoing Screening Colonoscopy: A Systematic Review and Meta-Analysis. Gastroenterology, 2021, 161, 1145-1155.e12.	1.3	31
63	Clinical and Genetic Characteristics of Colorectal Cancer in Persons under 50 Years of Age: A Review. Digestive Diseases and Sciences, 2019, 64, 3059-3065.	2.3	29
64	Prognostic Subgroups among Patients with Stage II Colon Cancer. New England Journal of Medicine, 2016, 374, 277-278.	27.0	27
65	MicroRNA miR-J1-5p as a potential Biomarker for JC Virus Infection in the Gastrointestinal Tract. PLoS ONE, 2014, 9, e100036.	2.5	25
66	Promoter Methylation in the Genesis of Gastrointestinal Cancer. Yonsei Medical Journal, 2009, 50, 309.	2.2	23
67	Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome. Familial Cancer, 2015, 14, 259-264.	1.9	23
68	Colorectal Cancer in Persons Under Age 50. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 441-455.	1.4	23
69	Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors. Journal of Translational Medicine, 2018, 16, 5.	4.4	21
70	Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectalÂcancer. Gastrointestinal Endoscopy, 2016, 83, 489-498.e10.	1.0	20
71	Chromosomal instability and cancer: not just one CINgle mechanism. Gut, 2009, 58, 163-164.	12.1	19
72	Analysis of cancer-associated colonic mucin by ion-exchange chromatography: evidence for a mucin species of lower molecular charge and weight in cancer. Biochimica Et Biophysica Acta - General Subjects, 1989, 991, 284-295.	2.4	18

CLEMENT RICHARD BOLAND

#	Article	IF	CITATIONS
73	Recent discoveries in the molecular genetics of Lynch syndrome. Familial Cancer, 2016, 15, 395-403.	1.9	18
74	Chronic Inflammation, Colorectal Cancer and Gene Polymorphisms. Digestive Diseases, 2010, 28, 590-595.	1.9	16
75	Novel candidates in early-onset familial colorectal cancer. Familial Cancer, 2020, 19, 1-10.	1.9	13
76	Managing gastric cancer risk in lynch syndrome: controversies and recommendations. Familial Cancer, 2022, 21, 75-78.	1.9	10
77	The genetic and epigenetic landscape of early-onset colorectal cancer. Colorectal Cancer, 2020, 9, .	0.8	9
78	Colorectal Advanced Neoplasms Occur through Dual Carcinogenesis Pathways in Individuals with Coexisting Serrated Polyps. PLoS ONE, 2014, 9, e98059.	2.5	9
79	Immune response to JC virus T antigen in patients with and without colorectal neoplasia. Gut Microbes, 2014, 5, 468-475.	9.8	8
80	Characterization and Identification of Colorectal Cancer in Persons Younger Than 50 Years. Clinical Gastroenterology and Hepatology, 2019, 17, 2600-2602.	4.4	8
81	Review article: Lynch Syndrome—a mechanistic and clinical management update. Alimentary Pharmacology and Therapeutics, 2022, 55, 960-977.	3.7	8
82	JC virus: a biomarker for colorectal cancer?. Medical Hypotheses, 2002, 59, 667-669.	1.5	7
83	Constraints imposed by supercoiling on in vitro amplification of polyomavirus DNA. Journal of General Virology, 2004, 85, 3383-3388.	2.9	7
84	Novel Mutations inMLH1andMSH2Genes in Mexican Patients with Lynch Syndrome. Gastroenterology Research and Practice, 2016, 2016, 1-6.	1.5	6
85	Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2017, 112, 682-690.	0.4	6
86	Effect of aspirin on tumour cell colony formation and evolution. Journal of the Royal Society Interface, 2017, 14, 20170374.	3.4	6
87	<i>TFAP2E</i> Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer. Clinical Cancer Research, 2018, 24, 2820-2827.	7.0	6
88	Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2022, 95, 1025-1047.	1.0	6
89	"New―Cancer Genes and Inherited Colorectal Cancer Risk: Caveat Emptor. Gastroenterology, 2017, 152, 12-13.	1.3	5
90	Genetic Testing Use and Expectations in Early Onset Colorectal Cancer. Current Treatment Options in Gastroenterology, 2020, 18, 589-603.	0.8	5

#	Article	IF	CITATIONS
91	Aspirin and the chemoprevention of cancers: A mathematical and evolutionary dynamics perspective. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2020, 12, e1487.	6.6	5
92	The changing scope of colorectal cancer. Gut, 2001, 48, 449a-450.	12.1	4
93	A rat virus visits the clinic: translating basic discoveries into clinical medicine in the 21st century. Gut, 2003, 52, 8-9.	12.1	4
94	Lynch syndrome: new tales from the crypt. Lancet Oncology, The, 2012, 13, 562-564.	10.7	3
95	Taking the starch out of hereditary colorectal cancer. Lancet Oncology, The, 2012, 13, 1179-1180.	10.7	3
96	Interval Colorectal Cancer 2006–2015: Novel Observations. Digestive Diseases and Sciences, 2021, 66, 855-860.	2.3	3
97	Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia. Epigenomics, 2020, 12, 2173-2187.	2.1	3
98	Correspondence: Reply to †̃SEMA4A variation and risk of colorectal cancer'. Nature Communications, 2016, 7, 10695.	12.8	2
99	Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on ColorectalÂCancer. Gastrointestinal Endoscopy, 2017, 85, 873-882.	1.0	2
100	Evaluation and management of Lynch syndrome. Clinical Advances in Hematology and Oncology, 2007, 5, 851,873.	0.3	2
101	Molecular screening for Lynch syndrome. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 392-393.	1.7	1
102	Our New President—John M. Carethers, MD, AGAF. Gastroenterology, 2022, 162, 1732-1736.	1.3	1
103	Preventing Colon Cancer: Looking Over the Horizon. Baylor University Medical Center Proceedings, 2003, 16, 344-345.	0.5	0
104	Diagnosis of Malignant Potential in Mucinous Peritoneal Neoplasms by Characterization of Mucin Carbohydrate Structure. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 108-109.e2.	4.5	0
105	Reply. Gastroenterology, 2018, 154, 2274-2275.	1.3	0
106	Henry T. Lynch, MD (January 4, 1928–June 2, 2019). Gastroenterology, 2019, 157, 905-906.	1.3	0
107	Hunting for the Holy Grail in Colorectal Cancer. Gastroenterology, 2020, 158, 2047-2049.	1.3	0
108	Preoperative serum microRNA-203 as a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Journal of Clinical Oncology, 2015, 33, 564-564.	1.6	0

#	Article	IF	CITATIONS
109	Polyp Biology. , 0, , 347-357.		0